# Specification Quality Checklist: Observe Live GDScript Editor State Safely

**Purpose**: Validate specification completeness and quality before proceeding to planning

**Created**: 2026-09-26

**Feature**: [spec.md](../spec.md)

**Review Ownership**: Requirements-quality review maintained by `/speckit.specify` and `/speckit.clarify`.

**Marker Semantics**: `[x]` means the requirement-quality criterion has been reviewed and satisfied. It does not mean implementation work or real-editor validation is complete.

## Content Quality

- [x] No implementation details (languages, frameworks, APIs)
- [x] Focused on user value and business needs
- [x] Written for non-technical stakeholders
- [x] All mandatory sections completed

## Requirement Completeness

- [x] No [NEEDS CLARIFICATION] markers remain
- [x] Requirements are testable and unambiguous
- [x] Success criteria are measurable
- [x] Success criteria are technology-agnostic (no implementation details)
- [x] All acceptance scenarios are defined
- [x] Edge cases are identified
- [x] Scope is clearly bounded
- [x] Dependencies and assumptions identified

## Feature Readiness

- [x] All functional requirements have clear acceptance criteria
- [x] User scenarios cover primary flows
- [x] Feature meets measurable outcomes defined in Success Criteria
- [x] No implementation details leak into specification

## Notes

- Items marked incomplete require spec updates before `/speckit.clarify` or `/speckit.plan`.
- Review completed 2026-09-26: all 16 criteria pass; no unresolved clarification markers or requirements-quality issues found.
- Content and scope: the four user stories explain the caller/developer outcome; D/R/B are defined before use. Godot/GDScript name the required product domain, not a selected implementation stack. Assumptions explicitly leave implementation mechanisms unselected.
- Observation semantics: “it does not mean the three sources agree or that a later edit is safe” separates successful observation from successful mutation. FR-005–FR-009 and User Stories 1–2 require independent sources, independent dirty state, and truthful divergence.
- Limitations: User Story 4 and FR-004/FR-006/FR-010 distinguish confirmed closed, missing/invalid, open-but-unobservable, and unknown-open-state cases. “Not applicable because no open buffer exists” applies only to a confirmed closed document, not a failed buffer read.
- Targeting/freshness: User Story 3 and FR-001–FR-003/FR-012–FR-015 cover exact target selection, ambiguity, session replacement, disconnection, partial evidence, and deadlines. User Story 2 scenario 4 and FR-013 cover detectable changes without promising an atomic snapshot.
- Read-only/security: User Story 1 scenario 2, User Story 3 scenarios 1 and 7, User Story 4 scenario 1, and SC-005 make FR-011/FR-016 observable: preserve human work, refuse out-of-scope targets, and cause no writes or editor/history changes. FR-016 separately prohibits source retention in incidental logs and telemetry.
- Governance requirements: FR-017 is bounded by “Scope and Governance Alignment” (no MCP, no second safety model, no gameplay authority). FR-018 defines the evidence required before version support may be claimed. Planning/review retain those acceptance obligations rather than selecting their implementation here.
- Measurable outcomes: SC-001–SC-003 require correct results across all defined cases; SC-004 defines a five-second bound; SC-005 requires zero observer-caused changes over 20 observations; SC-006 checks whether the result answers the user's questions without inference. The deadline is identified as an assumption, not measured performance.
- Scope review: the specification links all four governing documents, records why mutation-specific gates do not apply to this read-only feature, and explicitly disclaims Phase 1 completion. Missing observability cannot waive the positive clean/dirty acceptance scenarios.
- These marks validate the specification, not an implementation. Real-Godot scenarios are defined but have not been executed during specification generation. No product support, performance, mutation safety, or release-readiness claim is made.
